1. Introduction {#sec1}
===============

Cholangiocarcinoma (CCa) is a malignant tumor arising from the epithelium of the bile ducts and is usually classified by anatomical and clinical criteria into intrahepatic cholangiocarcinoma (IH-CCa), hilar cholangiocarcinoma (H-CCa), and extrahepatic cholangiocarcinoma (EH-CCa) \[[@B1]\]. CCa has a poor prognosis and surgical resection with appropriate lymph node dissection is advocated as the curative approach in some patients \[[@B2]\]. Consequently, accurate evaluation and staging are critical to provide indication to surgery and to avoid unnecessary surgical interventions \[[@B3]\].

Several diagnostic tools have been used in this setting, including ultrasonography (US), computed tomography (CT), magnetic resonance (MR), endoscopic retrograde cholangiopancreatography (ERCP), and percutaneous transhepatic cholangiography (PTC).

Fluorine-18-fluorodeoxyglucose (^18^F-FDG) positron emission tomography (PET) and PET/CT have been proposed as noninvasive imaging methods to assess the disease extent in cancer patients \[[@B4]\]. Since ^18^F-FDG is a glucose analogue, this radiopharmaceutical may be very useful in detecting malignant lesions which usually present high glucose metabolism. Hybrid PET/CT device allows enhanced detection and characterization of neoplastic lesions, by combining the functional data obtained by PET with morphological data obtained by CT \[[@B4]\].

Several studies have assessed the diagnostic accuracy of ^18^F-FDG-PET or PET/CT in the evaluation of primary tumor in patients with CCa, reporting different values of sensitivity and specificity. The purpose of our study is to meta-analyze published data on the diagnostic accuracy of ^18^F-FDG-PET or PET/CT in the evaluation of primary tumor in patients with CCa, in order to provide more evidence-based data and to address further studies in this setting.

2. Materials and Methods {#sec2}
========================

2.1. Search Strategy {#sec2.1}
--------------------

A comprehensive computer literature search of PubMed/MEDLINE and Embase databases was carried out to find relevant published articles concerning the evaluation of primary tumor in patients with CCa. We used a search algorithm based on a combination of terms ("PET" or "positron emission tomography") and ("cholangiocarcinoma" or "cholangiocellular" or "cholangio∗" or "biliar" or "biliary" or "bile" or "Klatskin"). Only articles in English language were considered. The search was performed from inception to December 31, 2013. To expand our search, references of the retrieved articles were also screened for additional studies.

2.2. Study Selection {#sec2.2}
--------------------

Studies or subsets in studies investigating the role of ^18^F-FDG-PET or PET/CT in the evaluation of primary CCa were eligible for inclusion. Case reports, small case series, review articles, letters, editorials, and conference proceedings were excluded. The following inclusion criteria were applied to select studies for this meta-analysis:original studies in which ^18^F-FDG-PET or PET/CT were performed in patients with CCa or suspicious CCa;a sample size of at least ten patients with CCa or suspicious CCa;sufficient data to reassess sensitivity and specificity of ^18^F-FDG-PET or PET/CT in detecting the primary tumor in patients with CCa;no data overlap.

Three researchers (SA, DAP, and CC) independently reviewed titles and abstracts of the retrieved articles, applying the above-mentioned selection criteria. Articles were rejected if they were clearly ineligible. The same three researchers then independently evaluated the full-text version of the included articles to determine their eligibility for inclusion.

2.3. Data Extraction {#sec2.3}
--------------------

Information about basic study (authors, year of publication, and country of origin), study design (prospective or retrospective), patients\' characteristics (number of patients with biliary ducts lesions performing ^18^F-FDG-PET or PET/CT, mean age, and gender), and technical aspects (injected activity of ^18^F-FDG and time between injection and image acquisition) was collected.

Each study was analyzed to retrieve the number of true-positive (TP), true-negative (TN), false-positive (FP), and false-negative (FN) findings of ^18^F-FDG-PET or PET/CT in patients with CCa or suspicious CCa, according to the reference standard. Only studies providing such complete information were finally included in the meta-analysis.

2.4. Quality Assessment {#sec2.4}
-----------------------

The 2011 Oxford Center for Evidence-Based Medicine checklist for diagnostic studies was used for quality assessment of the included studies. This checklist has 5 major parts as follows: representative spectrum of the patients, consecutive patient recruitment, ascertainment of the gold standard regardless of the index test results, independent blind comparison between the gold standard and index test results, and enough explanation of the test to permit replication.

2.5. Statistical Analysis {#sec2.5}
-------------------------

Sensitivity and specificity of ^18^F-FDG-PET and PET/CT in the evaluation of primary CCa were obtained from the individual studies, on a per patient-based analysis. We considered as positive a biliary ducts lesion with increased uptake of ^18^F-FDG, according to the criteria reported by the different authors. When a positive lesion was histologically confirmed as malignant, this was considered a TP lesion, whereas a histologically confirmed benign lesion was considered as a FP lesion. We considered as negative a lesion with no uptake of ^18^F-FDG: when the lesion was histologically confirmed as malignant, this was considered as FN lesion, whereas a histologically confirmed benign lesion was considered as a TN lesion.

Sensitivity was determined according to the following formula: TP/(TP + FN); specificity was determined according to this following formula: TN/(TN + FP). Statistical pooling of the data was performed by means of a random effects model. Pooled data are presented with 95% confidence intervals (95% CI). Heterogeneity between studies was assessed by an *I* ^2^ index. A summary receiving operator characteristics (ROC) curve was obtained for selected studies and area under the curve (AUC) was calculated to assess the overall accuracy of ^18^F-FDG-PET and PET/CT.

Subsequently, subgroup analyses were also performed, calculating the pooled sensitivity and specificity of ^18^F-FDG-PET and PET/CT in three different groups of primary CCa (IH-CCa, EH-CCa, and H-CCa) and in two groups based on the different device used (PET or PET/CT).

For publication bias evaluation, funnel plots, Egger\'s regression intercept, and Duval and Tweedie\'s method were used \[[@B5]\].

Statistical analyses were performed using Meta-DiSc statistical software version 1.4.

3. Results {#sec3}
==========

3.1. Literature Search {#sec3.1}
----------------------

The comprehensive computer literature search from PubMed/MEDLINE and Embase databases revealed 449 articles. Reviewing titles and abstracts, 406 records were excluded as reviews, editorials or letters, case reports or case series, or no direct link with the main subject. Twenty articles were excluded due to absence of data to reassess the pooled sensitivity or specificity of ^18^F-FDG-PET or PET/CT in evaluating the primary tumor in patients with CCa or suspicious CCa. Finally, 23 articles including 1232 patients were selected and were eligible for the meta-analysis \[[@B1]--[@B3], [@B6]--[@B25]\]; no additional studies were found screening the references of these articles ([Figure 1](#fig1){ref-type="fig"}). The characteristics of the included studies are presented in Tables [1](#tab1){ref-type="table"}, [2](#tab2){ref-type="table"}, [3](#tab3){ref-type="table"} and [4](#tab4){ref-type="table"}.

3.2. Qualitative Analysis (Systematic Review) {#sec3.2}
---------------------------------------------

Using the database search, 23 original articles written over the past 12 years were selected \[[@B1]--[@B3], [@B6]--[@B25]\]. About the study design, 7 of these studies were prospective \[[@B6], [@B7], [@B13], [@B14], [@B17]--[@B19]\] and 12 were retrospective \[[@B1]--[@B3], [@B9], [@B12], [@B15], [@B16], [@B20]--[@B22], [@B24], [@B25]\] and in 4 articles this information was not provided \[[@B8], [@B10], [@B11], [@B23]\].

Ten studies used hybrid PET/CT \[[@B1]--[@B3], [@B11], [@B13], [@B18], [@B19], [@B21]--[@B23]\], whereas thirteen studies used PET only \[[@B6]--[@B10], [@B12], [@B14]--[@B17], [@B20], [@B24], [@B25]\]. Heterogeneous technical aspects between the included studies were found ([Table 2](#tab2){ref-type="table"}). PET image analysis was performed by using qualitative criteria (visual analysis) in all the included studies \[[@B1]--[@B3], [@B6]--[@B25]\] and adjunctive semiquantitative criteria (based on the calculation of the standardized uptake value (SUV)) in 19 articles \[[@B1]--[@B3], [@B6]--[@B9], [@B11], [@B13], [@B15], [@B16], [@B18]--[@B25]\]. One study used quantitative criteria (based on blood sampling and the Gjedde-Patlak linearization procedure) \[[@B14]\].

The reference standard used to validate the ^18^F-FDG-PET or PET/CT findings in the included studies was quite different ([Table 4](#tab4){ref-type="table"}). The results of the quality assessment of the studies included in this systematic review, according to the 2011 Oxford Center for Evidence-Based Medicine checklist for diagnostic studies, are shown in [Table 4](#tab4){ref-type="table"}.

3.3. Quantitative Analysis (Meta-Analysis) {#sec3.3}
------------------------------------------

The diagnostic accuracy values of ^18^F-FDG-PET and PET/CT in the 23 studies included in the meta-analysis are presented in Figures [2](#fig2){ref-type="fig"}--[4](#fig4){ref-type="fig"}. All the 23 studies had sufficient data to calculate the pooled sensitivity \[[@B1]--[@B3], [@B6]--[@B25]\], whereas only 13 studies \[[@B1], [@B7], [@B10]--[@B16], [@B18], [@B20]--[@B22]\] provided information about TN and FP lesions, thus allowing assessment of pooled specificity.

Sensitivity and specificity values of ^18^F-FDG-PET or PET/CT on a per patient-based analysis ranged from 59 to 100% and from 63 to 100%, with pooled estimates of 81% (95% CI: 78--83%) and 82% (95% CI: 75--87%), respectively. The area under the summary ROC curve was 0.89. The included studies showed statistical heterogeneity in their estimate of sensitivity (*I* ^2^: 63.7%).

Egger\'s regression intercepts for sensitivity and specificity pooling were 1.9 (95% CI: 0.3 to 3.5, *P* = 0.02) and −0.7 (95% CI: −2.4 to 0.9, *P* = 0.35), respectively. Applying Duval and Tweedie\'s method, the funnel plot of sensitivity and specificity reached symmetry and the adjusted sensitivity and specificity decreased 2.4% and increased 1.8%, respectively ([Figure 2](#fig2){ref-type="fig"}).

To reduce the heterogeneity, subgroup analyses considering the different device used (PET or PET/CT) were performed ([Figure 4](#fig4){ref-type="fig"}). In studies in which ^18^F-FDG-PET was used, values of sensitivity (thirteen eligible studies) and specificity (seven eligible studies) on a per patient-based analysis ranged from 60 to 95% and from 67 to 95%, respectively, with pooled estimates of 80% (95% CI: 76--83%) and 89% (95% CI: 80--95%), respectively. Statistical heterogeneity was found only in their estimate of sensitivity (*I* ^2^: 63%). The area under the ROC curve was 0.92.

In studies in which hybrid ^18^F-FDG-PET/CT was used, values of sensitivity (ten eligible studies) and specificity (six eligible studies) on a per patient-based analysis ranged from 59 to 100% and from 63 to 100%, respectively, with pooled estimates of 82% (95% CI: 78--85%) and 75% (95% CI: 65--84%), respectively. Statistical heterogeneity was found only in their estimate of sensitivity (*I* ^2^: 67%). The area under the ROC curve was 0.81.

Finally, subgroup analyses considering different anatomic sites of CCa (IH-CCa, EH-CCa, and H-CCa) were carried out ([Figure 3](#fig3){ref-type="fig"}). In patients with IH-CCa, values of sensitivity (nine eligible studies) and specificity (five eligible studies) on a per patient-based analysis ranged from 91 to 100% and from 80 to 100%, respectively, with pooled estimates of 95% (95% CI: 91--98%) and 83% (95% CI: 64--94%), respectively. No statistical heterogeneity was found, among the included studies, in both the estimate of sensitivity and the estimate of specificity (*I* ^2^: 0%). The area under the ROC curve was 0.95.

In patients with EH-CCA, values of sensitivity (twelve eligible studies) and specificity (seven eligible studies) on a per patient-based analysis ranged from 52 to 92% and from 33 to 100%, respectively, with pooled estimates of 76% (95% CI: 71--80%) and 74% (95% CI: 58--87%), respectively. Statistical heterogeneity was found only in their estimate of sensitivity (*I* ^2^: 61%). The area under the ROC curve was 0.82.

In patients with H-CCA, values of sensitivity (eight eligible studies) and specificity (three eligible studies) on a per patient-based analysis ranged from 59 to 100% and from 93 to 100%, respectively, with pooled estimates of 84% (95% CI: 76--89%) and 95% (95% CI: 82--99%), respectively. No significant statistical heterogeneity was found in their estimate of sensitivity (*I* ^2^: 48%) and specificity (*I* ^2^: 0%). The area under the ROC curve was 0.98.

4. Discussion {#sec4}
=============

To the best of our knowledge, this meta-analysis is the first to evaluate the diagnostic accuracy of ^18^F-FDG-PET or PET/CT in the evaluation of primary tumor in patients with CCa \[[@B26]\]. Several studies have used ^18^F-FDG-PET or PET/CT in this setting reporting different values of sensitivity and specificity. However, many of these studies have limited power, analyzing only relatively small numbers of patients. In order to derive more robust estimates of the diagnostic accuracy of ^18^F-FDG-PET or PET/CT in this setting we pooled published studies. A systematic review process was adopted in ascertaining studies, thereby avoiding selection bias.

Pooled results of our meta-analysis indicate that ^18^F-FDG-PET or PET/CT have a good sensitivity (81%) and specificity (82%) in the evaluation of primary tumor in patients with CCa. Furthermore, the value of the AUC (0.89) demonstrates that ^18^F-FDG-PET or PET/CT are accurate diagnostic methods in this setting. Considering patients with all anatomical localizations of primary CCa, independently of the device used (PET or PET/CT), significant heterogeneity between the studies in their estimate of sensitivity was found (*I* ^2^: 63.7%). In order to reduce possible source of heterogeneity, subgroup analyses considering different device used (PET or PET/CT) and patients with different anatomical localizations (IH-, H-, and EH-CCa) were performed.

These subgroup analyses provide differences in the diagnostic accuracy data for various anatomical localizations. ^18^F-FDG-PET and PET/CT seem to be more sensitive and specific in the evaluation of primary tumor in patients with IH-CCA than in patients with H-CCA and EH-CCA.

In particular ^18^F-FDG-PET and PET/CT have a moderate diagnostic accuracy in evaluating primary EH-CCa (sensitivity of 76% and specificity of 74%). In this setting, sensitivity and specificity of ^18^F-FDG-PET and PET/CT may be affected by FN (due to the confounding anatomical localization of extrahepatic bile ducts) and FP (due to inflammation of extrahepatic bile ducts). Larger use of hybrid PET/CT and, consequently, further studies about the role of PET/CT in evaluation of primary tumour in patients with EH-CCA may improve these results.

Conversely, the diagnostic accuracy of ^18^F-FDG-PET and PET/CT in primary IH-CCA (sensitivity of 95% and specificity of 83%) seems to be better than in the other anatomical localizations of primary CCa. Possible explanations are the easier individuation of illness in the liver parenchyma and the small number of FP cases (intrahepatic noncancerous disease positive with ^18^F-FDG-PET). Further studies are needed to evaluate if different histological types of IH-CCA (nodular or mass-forming type, infiltrating type, and intraluminal type) could cause different diagnostic accuracy of ^18^F-FDG-PET and PET/CT in this setting.

Finally, the diagnostic accuracy of ^18^F-FDG-PET and PET/CT in evaluating primary H-CCa is good (sensitivity of 84% and specificity of 95%). Nevertheless, we cannot exclude that the low number of the included studies in this subgroup analysis may have influenced the results. FP findings (due to the presence of ^18^F-FDG-avid lymph nodes in the hepatic hilum) and FN results (due to the difficult anatomical localization of the hepatic hilum) should be considered. More studies are needed to further evaluate sensitivity and specificity of ^18^F-FDG-PET and PET/CT in primary H-CCa.

However, performing these subgroup analyses has been useful in demonstrating that the anatomical localization of primary tumor (IH-CCa, EH-CCa, or H-CCA) is a source of heterogeneity among the studies. In fact, no significant heterogeneity was found in the subgroup analyses performed, except in the calculation of pooled sensitivity of ^18^F-FDG-PET or PET/CT in primary EH-CCA.

Pooled sensitivity is similar in the subgroup analyses regarding different device used (80% for PET and 82% for PET/CT, resp.). Nevertheless, heterogeneity was found in these groups, in particular for the calculation of pooled sensitivity, suggesting that, beyond the device used, other factors (such as the anatomical localization of the primary CCa) seem to be a stronger source of heterogeneity. PET alone seems to be more specific than PET/CT (89% and 75%, resp.). A possible explanation of these surprising findings could be the higher number of patients with primary EH-CCa included in the studies which performed PET/CT compared to those which performed PET only.

Finally, regarding the diagnostic workup of patients with CCa, ^18^F-FDG-PET and PET/CT may have little diagnostic advantage over traditional imaging modalities in detecting the primary CCA \[[@B3]\]. ^18^F-FDG-PET and PET/CT can be complementary to CT and MR in the diagnosing and staging of CCA \[[@B20]\]. Since ^18^F-FDG-PET imaging is a whole-body scanning technique, it allows detection of unsuspected metastatic lymph nodes or distant spread that may lead to major changes in the surgical management of patients with biliary tract cancer \[[@B25]\]. Nevertheless, the diagnostic performance of ^18^FDG-PET or PET/CT in detecting metastatic lymph nodes or distant spread was not object of our analysis.

This study has several limitations. Different anatomical classifications of CCa were used by several studies. For example, it is likely that some H-CCa were classified as EH-CCa by some studies. Other possible limitations of our meta-analysis could be the heterogeneity between the included studies (nevertheless subgroup analyses were performed to reduce the heterogeneity) and the possible publication bias. We assessed publication bias in our meta-analysis using qualitative and quantitative methods (Egger\'s regression and Duval and Tweedie\'s method). Funnel plots showed the importance of possible publication bias in particular for the estimation of pooled sensitivity ([Figure 2](#fig2){ref-type="fig"}).

Overall, ^18^F-FDG-PET and PET/CT were demonstrated to be accurate noninvasive tools in the evaluation of primary tumors in patients with CCa. Furthermore, more studies in patients with H-CCa and cost-effectiveness analyses of the role of ^18^F-FDG-PET or PET/CT in this setting are needed.

5. Conclusions {#sec5}
==============

^18^F-FDG-PET and PET/CT were demonstrated to be accurate diagnostic imaging methods in the evaluation of primary tumors in patients with CCa. These tools seem to have a better diagnostic accuracy in the evaluation of primary IH-CCa compared to EH-CCa. Further studies are needed to evaluate the accuracy of ^18^F-FDG-PET and PET/CT in assessing primary H-CCa.
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###### 

Basic characteristics of the included studies.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors                             Year   Country       Study design    Patients performing ^18^F-FDG-PET or PET/CT   Mean age\   Gender\    Site of primary tumour
                                                                                                                         (years)     (% male)   
  ----------------------------------- ------ ------------- --------------- --------------------------------------------- ----------- ---------- ------------------------------------
  Fritscher-Ravens et al. \[[@B6]\]   2001   Germany       Prospective     15                                            58          60%        15 H-CCa

                                                                                                                                                

  Kluge et al. \[[@B7]\]              2001   Germany       Prospective     54                                            NR          54%        NR

                                                                                                                                                

  Kato et al. \[[@B8]\]               2002   Japan         NR              30                                            68          70%        30 EH-CCa

                                                                                                                                                

  Kim et al. \[[@B9]\]                2003   Korea         Retrospective   21                                            57          52%        10 H -CCa and 11 IH-CCa

                                                                                                                                                

  Anderson et al. \[[@B10]\]          2004   USA           NR              36                                            63          55%        NR

                                                                                                                                                

  Reinhardt et al. \[[@B11]\]         2005   Germany       NR              20                                            63          50%        20 H-CCa

                                                                                                                                                

  Wakabayashi et al. \[[@B12]\]       2005   Japan         Retrospective   30                                            71          50%        5 IH-CCa and 25 EH-CCa

                                                                                                                                                

  Petrowsky et al. \[[@B13]\]         2006   Switzerland   Prospective     61                                            64          51%        14 IH-CCa and 33 EH-CCa

                                                                                                                                                

  Prytz et al. \[[@B14]\]             2006   Sweden        Prospective     24                                            39          83%        NR

                                                                                                                                                

  Nishiyama et al. \[[@B15]\]         2007   Japan         Retrospective   37                                            70          59%        29 EH-CCa

                                                                                                                                                

  Corvera et al. \[[@B16]\]           2008   USA           Retrospective   126                                           62          52%        41 EH-CCa and 21 IH-CCa

                                                                                                                                                

  Furukawa et al. \[[@B17]\]          2008   Japan         Prospective     72                                            69          57%        64 EH-CCa

                                                                                                                                                

  Kim et al. \[[@B18]\]               2008   Korea         Prospective     123                                           60          65%        36 IH-CCa and 87 EH-CCa

                                                                                                                                                

  Li et al. \[[@B19]\]                2008   Germany       Prospective     17                                            62          65%        17 H-CCa

                                                                                                                                                

  Moon et al. \[[@B20]\]              2008   Korea         Retrospective   54                                            59          63%        23 IH-CCa, 12 H-CCa, and 11 EH-CCa

                                                                                                                                                

  Lee et al. \[[@B21]\]               2010   Korea         Retrospective   99                                            67          59%        17 IH-CCa and 49 EH-CCa

                                                                                                                                                

  Alkhawaldeh et al. \[[@B22]\]       2011   Germany       Retrospective   65                                            63          60%        34 H-CCa and 23 IH-CCa

                                                                                                                                                

  Kitamura et al. \[[@B23]\]          2011   Japan         NR              73                                            66          63%        45 H-CCa and 28 EH-CCa

                                                                                                                                                

  Ruys et al. \[[@B24]\]              2011   Netherlands   Retrospective   30                                            62          47%        26 H-CCa

                                                                                                                                                

  Yamada et al. \[[@B25]\]            2012   Japan         Retrospective   73                                            68          63%        16 IH-CCa, 18 H-CCa, and 20 EH-CCa

                                                                                                                                                

  Albazaz et al. \[[@B3]\]            2013   UK            Retrospective   81                                            65          41%        47 IH-CCa and 34 EH-CCa

                                                                                                                                                

  Choi et al. \[[@B1]\]               2013   Korea         Retrospective   39                                            64          72%        34 EH-CCa

                                                                                                                                                

  Lee et al. \[[@B2]\]                2013   Korea         Retrospective   52                                            69          53%        23 EH-CCa, 17 H-CCa, and 12 IH-CCa
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NR: not reported; H-CCa: hilar cholangiocarcinoma; EH-CCa: extrahepatic cholangiocarcinoma; IH-CCa: intrahepatic cholangiocarcinoma.

###### 

Technical characteristics of the included studies.

  Authors                             Year   Device   ^18^F-FDG mean injected dose (MBq)   Time between ^18^F-FDG injection and image acquisition (min)   Image analysis                Other imaging methods performer
  ----------------------------------- ------ -------- ------------------------------------ -------------------------------------------------------------- ----------------------------- ---------------------------------
  Fritscher-Ravens et al. \[[@B6]\]   2001   PET      Range: 320--400                      60                                                             Visual and semiquantitative   CT and ERCP
                                                                                                                                                                                        
  Kluge et al. \[[@B7]\]              2001   PET      370                                  50                                                             Visual and semiquantitative   US, CT, MR, and ERCP
                                                                                                                                                                                        
  Kato et al. \[[@B8]\]               2002   PET      NR                                   60                                                             Visual and semiquantitative   CT
                                                                                                                                                                                        
  Kim et al. \[[@B9]\]                2003   PET      370                                  60                                                             Visual and semiquantitative   CR, MR, ERCP, and PTC
                                                                                                                                                                                        
  Anderson et al. \[[@B10]\]          2004   PET      370                                  60                                                             Visual                        CT and MR
                                                                                                                                                                                        
  Reinhardt et al. \[[@B11]\]         2005   PET/CT   369                                  101                                                            Visual and semiquantitative   ERCP
                                                                                                                                                                                        
  Wakabayashi et al. \[[@B12]\]       2005   PET      185                                  60                                                             Visual                        CT, ERCP, and PTC
                                                                                                                                                                                        
  Petrowsky et al. \[[@B13]\]         2006   PET/CT   370                                  45                                                             Visual and semiquantitative   CT, ERCP, and PTC
                                                                                                                                                                                        
  Prytz et al. \[[@B14]\]             2006   PET      300                                  Dynamic 0--90                                                  Visual and quantitative       US, CT, MR, ERCP, and PTC
                                                                                                                                                                                        
  Nishiyama et al. \[[@B15]\]         2007   PET      3/kg                                 70                                                             Visual and semiquantitative   US, CT, and MR
                                                                                                                                                                                        
  Corvera et al. \[[@B16]\]           2008   PET      Range: 370--555                      NR                                                             Visual and semiquantitative   US, CT, and MR
                                                                                                                                                                                        
  Furukawa et al. \[[@B17]\]          2008   PET      Range: 200--250                      60                                                             Visual                        US and CT
                                                                                                                                                                                        
  Kim et al. \[[@B18]\]               2008   PET/CT   370                                  60                                                             Visual and semiquantitative   CR, CT, MR, ERCP, and PTC
                                                                                                                                                                                        
  Li et al. \[[@B19]\]                2008   PET/CT   350                                  60                                                             Visual and semiquantitative   CT, MR, and ERCP
                                                                                                                                                                                        
  Moon et al. \[[@B20]\]              2008   PET      370                                  60                                                             Visual and semiquantitative   CT
                                                                                                                                                                                        
  Lee et al. \[[@B21]\]               2010   PET/CT   Range: 370--555                      60                                                             Visual and semiquantitative   CT and ERCP
                                                                                                                                                                                        
  Alkhawaldeh et al. \[[@B22]\]       2011   PET/CT   2.52/kg                              100                                                            Visual and semiquantitative   ERCP
                                                                                                                                                                                        
  Kitamura et al. \[[@B23]\]          2011   PET/CT   250                                  60                                                             Visual and semiquantitative   US, CT, MR, ERCP, PTC, and HS
                                                                                                                                                                                        
  Ruys et al. \[[@B24]\]              2011   PET      296                                  50                                                             Visual and semiquantitative   CT, MR, ERCP, and PTC
                                                                                                                                                                                        
  Yamada et al. \[[@B25]\]            2012   PET      4.5/kg                               60                                                             Visual and semiquantitative   CT, MR, and ERCP
                                                                                                                                                                                        
  Albazaz et al. \[[@B3]\]            2013   PET-CT   400                                  60                                                             Visual and semiquantitative   CT and MR
                                                                                                                                                                                        
  Choi et al. \[[@B1]\]               2013   PET/CT   Range: 370--555                      60                                                             Visual and semiquantitative   US, CT, and MR
                                                                                                                                                                                        
  Lee et al. \[[@B2]\]                2013   PET/CT   Range: 370--555                      60                                                             Visual and semiquantitative   US, CT, MR, and ERCP

NR: not reported; CT: computed tomography; ERCP: endoscopic retrograde cholangiopancreatography; MR: magnetic resonance; US: ultrasonography; PTC: percutaneous transhepatic cholangiography; HS: hepatobiliary scintigraphy.

###### 

Diagnostic accuracy data of ^18^F-FDG-PET or PET/CT on a per patient-based analysis.

  Author                              Year   Overall   PET   PET/CT   IH-CCa   H-CCa   EH-CCa                                                                                        
  ----------------------------------- ------ --------- ----- -------- -------- ------- -------- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ----
  Fritscher-Ravens et al. \[[@B6]\]   2001   10        2     3        0        10      2        3    0    NR   NR   NR   NR   NR   NR   NR   NR   10   2    3    0    NR   NR   NR   NR
                                                                                                                                                                                     
  Kluge et al. \[[@B7]\]              2001   24        2     2        26       24      2        2    26   NR   NR   NR   NR   NR   NR   NR   NR   24   2    2    26   NR   NR   NR   NR
                                                                                                                                                                                     
  Kato et al. \[[@B8]\]               2002   18        0     12       0        18      0        12   0    NR   NR   NR   NR   NR   NR   NR   NR   NR   NR   NR   NR   18   0    12   0
                                                                                                                                                                                     
  Kim et al. \[[@B9]\]                2003   20        0     1        0        20      0        1    0    NR   NR   NR   NR   11   0    0    0    9    0    1    0    NR   NR   NR   NR
                                                                                                                                                                                     
  Anderson et al. \[[@B10]\]          2004   19        1     12       4        19      1        12   4    NR   NR   NR   NR   NR   NR   NR   NR   NR   NR   NR   NR   NR   NR   NR   NR
                                                                                                                                                                                     
  Reinhardt et al. \[[@B11]\]         2005   19        2     2        7        19      2        2    7    NR   NR   NR   NR   2    0    0    3    NR   NR   NR   NR   12   2    1    2
                                                                                                                                                                                     
  Wakabayashi et al. \[[@B12]\]       2005   12        0     0        8        NR      NR       NR   NR   12   0    0    8    NR   NR   NR   NR   12   0    0    8    NR   NR   NR   NR
                                                                                                                                                                                     
  Petrowsky et al. \[[@B13]\]         2006   3         1     1        19       3       1        1    19   NR   NR   NR   NR   NR   NR   NR   NR   NR   NR   NR   NR   NR   NR   NR   NR
                                                                                                                                                                                     
  Prytz et al. \[[@B14]\]             2006   31        3     16       5        NR      NR       NR   NR   31   3    16   5    13   1    1    4    NR   NR   NR   NR   18   2    15   1
                                                                                                                                                                                     
  Nishiyama et al. \[[@B15]\]         2007   25        1     4        7        25      1        4    7    NR   NR   NR   NR   NR   NR   NR   NR   NR   NR   NR   NR   25   1    4    7
                                                                                                                                                                                     
  Corvera et al. \[[@B16]\]           2008   46        1     13       2        46      1        13   2    NR   NR   NR   NR   19   0    1    1    NR   NR   NR   NR   27   1    12   2
                                                                                                                                                                                     
  Furukawa et al. \[[@B17]\]          2008   40        0     7        0        40      0        7    0    NR   NR   NR   NR   NR   NR   NR   NR   NR   NR   NR   NR   40   0    7    0
                                                                                                                                                                                     
  Kim et al. \[[@B18]\]               2008   79        6     15       23       NR      NR       NR   NR   79   6    15   23   20   3    1    12   NR   NR   NR   NR   59   3    14   11
                                                                                                                                                                                     
  Li et al. \[[@B19]\]                2008   41        1     5        7        41      1        5    7    NR   NR   NR   NR   21   1    2    4    10   0    2    1    10   0    1    2
                                                                                                                                                                                     
  Moon et al. \[[@B20]\]              2008   10        0     7        0        NR      NR       NR   NR   10   0    7    0    NR   NR   NR   NR   10   0    7    0    NR   NR   NR   NR
                                                                                                                                                                                     
  Lee et al. \[[@B21]\]               2010   69        5     13       12       NR      NR       NR   NR   69   5    13   12   17   0    0    0    NR   NR   NR   NR   38   0    11   0
                                                                                                                                                                                     
  Alkhawaldeh et al. \[[@B22]\]       2011   45        6     2        12       NR      NR       NR   NR   45   6    2    12   NR   NR   NR   NR   NR   NR   NR   NR   NR   NR   NR   NR
                                                                                                                                                                                     
  Kitamura et al. \[[@B23]\]          2011   23        4     3        0        NR      NR       NR   NR   23   4    3    0    NR   NR   NR   NR   23   4    3    0    NR   NR   NR   NR
                                                                                                                                                                                     
  Ruys et al. \[[@B24]\]              2011   50        0     23       0        50      0        23   0    NR   NR   NR   NR   NR   NR   NR   NR   NR   NR   NR   NR   NR   NR   NR   NR
                                                                                                                                                                                     
  Yamada et al. \[[@B25]\]            2012   47        4     7        0        47      4        7    0    NR   NR   NR   NR   16   3    0    0    14   0    4    0    17   1    3    0
                                                                                                                                                                                     
  Albazaz et al. \[[@B3]\]            2013   48        1     14       0        NR      NR       NR   NR   48   1    14   0    36   0    3    0    NR   NR   NR   NR   12   1    11   0
                                                                                                                                                                                     
  Choi et al. \[[@B1]\]               2013   27        1     7        4        NR      NR       NR   NR   27   1    7    4    NR   NR   NR   NR   NR   NR   NR   NR   27   1    7    4
                                                                                                                                                                                     
  Lee et al. \[[@B2]\]                2013   51        0     10       0        NR      NR       NR   NR   51   0    10   0    NR   NR   NR   NR   NR   NR   NR   NR   NR   NR   NR   NR

NR: not reported; IH-CCa: intrahepatic cholangiocarcinoma; H-CCa: hilar cholangiocarcinoma; EH-CCa: extrahepatic cholangiocarcinoma; TP: true positive; FP: false positive; FN: false negative; TN: true negative.

###### 

Quality assessment of the included studies.

  First author/year                  Spectrum of patients                                                                                                                                                                           Consecutive or random selection of patients   Reference standard                                                   Application of reference standard regardless of indexed test           Enough explanation of the index test to ensure reproducibility   Independent blind comparison between index test and reference standard
  ---------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------- -------------------------------------------------------------------- ---------------------------------------------------------------------- ---------------------------------------------------------------- ------------------------------------------------------------------------
  Fritscher-Ravens, 2001 \[[@B6]\]   Patients with obstructive jaundice and hilar lesions                                                                                                                                           Yes                                           Histopathology                                                       Yes                                                                    Yes                                                              Yes
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Kluge, 2001 \[[@B7]\]              26 patients with CCa, 8 patients with benign bile duct stenosis, and 20 controls                                                                                                               No                                            Histopathology                                                       Yes                                                                    Yes                                                              Yes
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Kato, 2002 \[[@B8]\]               Patients with bile duct cancer                                                                                                                                                                 N/A                                           Histopathology                                                       Yes                                                                    Yes                                                              Yes
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Kim, 2003 \[[@B9]\]                Patients with intrahepatic CCa                                                                                                                                                                 N/A                                           Histopathology or clinical and radiological findings                 Yes                                                                    Yes                                                              No blinding
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Anderson, 2004 \[[@B10]\]          Patients suspected of CCa or gallbladder carcinoma                                                                                                                                             Yes                                           Histopathology or cytopathology                                      Yes                                                                    Yes                                                              No information regarding blinding
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Reinhardt, 2005 \[[@B11]\]         Patients with extrahepatic bile duct strictures on endoscopic retrograde cholangiography                                                                                                       Yes                                           Histopathology or cytopathology and imaging criteria and follow-up   No (patients with negative PET and cytology did not undergo surgery)   Yes                                                              No
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Wakabayashi, 2005 \[[@B12]\]       Patients with suspicious malignant biliary stricture                                                                                                                                           N/A                                           Histopathology (biopsy and surgical findings)                        Yes                                                                    Yes                                                              N/A
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Petrowsky, 2006 \[[@B13]\]         Patients with suspected or proven CCa or gallbladder cancer                                                                                                                                    Yes                                           Histopathology                                                       Yes                                                                    Yes                                                              Yes
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Prytz, 2006 \[[@B14]\]             Patients with primary sclerosing cholangitis within 2 weeks after listing for liver transplantation and with no evidence of malignancy on CT, magnetic resonance imaging, or ultrasonography   Yes                                           Histology of explanted livers                                        Yes                                                                    Yes                                                              Yes
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Nishiyama, 2007 \[[@B15]\]         Patients with biliary stricture who underwent PET imaging                                                                                                                                      Yes                                           Histopathology or cytology                                           Yes                                                                    Yes                                                              Yes
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Corvera, 2008 \[[@B16]\]           Patients with clinical diagnosis of biliary tract cancers                                                                                                                                      N/A                                           Histopathology                                                       Yes                                                                    Yes                                                              No
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Furukawa, 2008 \[[@B17]\]          Patients with suspected extrahepatic biliary cancers (bile duct dilatation and/or mass lesions detected by ultrasonography and CT)                                                             N/A                                           Histopathology and follow-up                                         Yes                                                                    Yes                                                              No (no blinding)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Kim, 2008 \[[@B18]\]               Patients with suspected CCa                                                                                                                                                                    Yes                                           Histopathology or follow-up                                          Yes                                                                    Yes                                                              Yes
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Li, 2008 \[[@B19]\]                Patients with clinically suspected or already established diagnosis of hilar CCa                                                                                                               N/A                                           Histopathology                                                       Yes                                                                    Yes                                                              N/A
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Moon, 2008 \[[@B20]\]              Patients with suspected CCa                                                                                                                                                                    Yes                                           Histopathology, cytopathology, or follow-up                          Yes                                                                    Yes                                                              Yes
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Lee, 2010 \[[@B21]\]               Patients with suspected CCa or gallbladder cancer                                                                                                                                              N/A                                           Histopathology or follow-up                                          Yes                                                                    Yes                                                              Yes
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Alkhawaldeh, 2011 \[[@B22]\]       Heterogeneous patients including patients with suspected CCa, patients with positive cytology for CCa, and patients with negative cytology                                                     No                                            Histopathology or follow-up                                          Yes                                                                    Yes                                                              N/A
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Kitamura, 2011 \[[@B23]\]          Patients with extrahepatic bile duct cancer                                                                                                                                                    Yes                                           Histopathology                                                       Yes                                                                    Yes                                                              No
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Ruys, 2011 \[[@B24]\]              Patients highly suspected of hilar CCa                                                                                                                                                         Yes                                           Histopathology                                                       Yes                                                                    Yes                                                              Yes
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Yamada, 2012 \[[@B25]\]            Patients with diagnosis of cancer of biliary tract                                                                                                                                             Yes                                           Histopathology                                                       Yes                                                                    Yes                                                              No
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Albazaz, 2013 \[[@B3]\]            Patients with primary biliary tumors                                                                                                                                                           Yes                                           Histopathology                                                       Yes                                                                    Yes                                                              Yes
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Choi, 2013 \[[@B1]\]               Patients with suspected extrahepatic malignancy based on imaging studies                                                                                                                       Yes                                           Histopathology or follow-up                                          Yes                                                                    Yes                                                              Yes
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Lee, 2013 \[[@B2]\]                Patients with confirmed biliary duct or gallbladder cancers                                                                                                                                    N/A                                           Histopathology or follow-up                                          Yes                                                                    Yes                                                              N/A

CCa: cholangiocarcinoma.
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